true Amended to correct hyperlink 0001635077 0001635077 2024-08-12 2024-08-12 0001635077 ACON:CommonStockParValue0.00001PerShareMember 2024-08-12 2024-08-12 0001635077 ACON:WarrantsEachExercisableForOneShareOfCommonStockMember 2024-08-12 2024-08-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K/A

Amendment #1

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 13, 2024 (August 12, 2024)

 

Aclarion, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware 001-41358 47-3324725
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)

 

8181 Arista Place, Suite 100  
Broomfield, Colorado 80021
(Address of Principal Executive Offices) (Zip Code)

 

Registrant’s telephone number, including area code: (833) 275-2266

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

  Trading  
Title of each class Symbol(s) Name of each exchange on which registered
Common Stock ACON Nasdaq Stock Market
Common Stock Warrants ACONW Nasdaq Stock Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

   

 

 

Explanatory Note

 

This Current Report on Form 8-K/A (this “Amendment”) is being filed to replace the version of Exhibit 10.1 (the “Initial Exhibit”) attached to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on August 12, 2024 (the “Initial 8-K”) and amends and restates the Initial 8-K in its entirety. Due to a clerical error, an incorrect version of the Initial Exhibit was attached as an exhibit to the Initial 8-K.

 

Item 1.01 Entry into a Material Definitive Agreement.

 

On August 12, 2024, Aclarion, Inc. (the “Company”), entered into a subscription agreement with an institutional investor, pursuant to which the Company agreed to issue and sell to the investor 400,000 shares (the “Shares”) of Common Stock of the Company at a price of $0.29 per share for gross proceeds to the Company of $116,000.

 

The Shares to be issued in the offering were offered at-the-market under Nasdaq rules and pursuant to the Company’s Form 1-A (the “Offering Statement”), initially filed by the Company with the Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended (the “Securities Act”), on June 11, 2024 and qualified on June 24, 2024.

 

The Shares were not placed through the efforts of a placement agent and no fees or commissions are to be paid on the transaction to anyone.

 

The Company has the ability, at its election, to raise additional proceeds of up to approximately $29.68 million on the same terms and conditions pursuant to the Offering Statement from time to time. Any additional sales made pursuant to the Offering Statement will be disclosed through subsequent prospectus supplements.

 

Notwithstanding that the Company desires to consummate one or more additional sales in the future, at this time the Company has no such additional oral or written agreements to consummate any such sales, and, as such, we cannot guarantee that any such sales will occur in the future.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits    
 

 

Exhibit

Number

  Description
       
  10.1  

Form of Subscription Agreement (Incorporated by reference to Exhibit 4.1 to the Company’s Form 1-A/A Offering Statement filed on June 20, 2024)

       
  104   Cover Page Interactive Data File - the cover page iXBRL tags are embedded within the Inline XBRL document

 

 

 

 

 

 

 

 

 2 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ACLARION, INC.
     
August 13, 2024 By:/s/ John Lorbiecki
  Name: John Lorbiecki
  Title: Chief Financial Officer

 

 

 

 

 

 

 

 

 

 

 

 

 3